The stock of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) hit a new 52-week high and has $28.76 target or 34.00% above today’s $21.46 share price. The 9 months bullish chart indicates low risk for the $1.02 billion company. The 1-year high was reported on Nov, 17 by Barchart.com. If the $28.76 price target is reached, the company will be worth $346.80 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 208,966 shares traded hands. Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has risen 66.90% since April 15, 2016 and is uptrending. It has outperformed by 62.28% the S&P500.
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Ratings Coverage
Out of 4 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Amphastar Pharmaceuticals has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Jefferies on Tuesday, January 19. The company was maintained on Tuesday, August 9 by Jefferies. The company was upgraded on Tuesday, August 18 by Zacks. Zacks downgraded Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) on Monday, August 10 to “Buy” rating. Needham maintained the stock with “Buy” rating in Tuesday, May 10 report. The stock of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has “Market Perform” rating given on Wednesday, June 29 by BMO Capital Markets. On Friday, February 19 the stock rating was initiated by Wells Fargo with “Outperform”.
According to Zacks Investment Research, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.”
Insitutional Activity: The institutional sentiment increased to 2.1 in 2016 Q2. Its up 0.43, from 1.67 in 2016Q1. The ratio improved, as 7 funds sold all Amphastar Pharmaceuticals Inc shares owned while 23 reduced positions. 19 funds bought stakes while 44 increased positions. They now own 15.47 million shares or 11.85% more from 13.83 million shares in 2016Q1.
Morgan Stanley holds 0% or 47,794 shares in its portfolio. Tfs Cap Ltd Llc has 46,859 shares for 0.14% of their US portfolio. Dimensional Fund Advsrs Lp reported 361,010 shares or 0% of all its holdings. Moreover, Blackrock Advisors Lc has 0% invested in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for 18,379 shares. Alliancebernstein L P holds 0% or 105,630 shares in its portfolio. Ubs Asset Americas owns 205,975 shares or 0% of their US portfolio. Pnc Incorporated has 104 shares for 0% of their US portfolio. Metropolitan Life Comm Ny last reported 0% of its portfolio in the stock. Financial Bank Of America Corporation De holds 0% or 12,760 shares in its portfolio. Moreover, Nationwide Fund Advsrs has 0% invested in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for 51,240 shares. C M Bidwell Assocs Limited, a Hawaii-based fund reported 12,820 shares. The Washington-based Fisher Asset Limited Com has invested 0.01% in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). City Hldgs Company last reported 0% of its portfolio in the stock. Strs Ohio last reported 47,900 shares in the company. Allianz Asset Mgmt Ag last reported 94,014 shares in the company.
Another recent and important Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) news was published by Fool.com which published an article titled: “Why Amphastar Pharmaceuticals, Inc. is Soaring Today” on September 20, 2016.
AMPH Company Profile
Amphastar Pharmaceuticals, Inc., incorporated on May 19, 2004, is a specialty pharmaceutical company. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment makes, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment makes and distributes recombinant human insulin and porcine insulin. The Firm makes and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.